Business
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitor WILMINGTON, Del.,
About this update from Prelude Therapeutics Incorporated
[{"type":"text","content":"Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitor\nWILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place from April 5 to 10, 2024. Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude, stated, “We look forward to sharing data on the preclinical characterization of our lead oral SMARCA2 degrader, PRT7732, which is on track to advance into Phase 1 clinical development in the second half of this year, and to presenting additional preclinical data for our highly selective and potent CDK9 inhibitor, PRT2527, that supports its potential therapeutic value in combination with BTK and BCL2 inhibitors in lymphoid malignancies. For our next generation CDK4/6 inhibitor, PRT3645, we will present preclinical data supporting its potential therapeutic value in combination with other targeted therapies for a range of tumor types in addition to breast cancer.” Details on the poster presentations are as follows: Title: Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2Presenter: Artem ShvartsbartSession Category: ChemistrySession Title: Targeted Protein DegradationSession Date and Time: Tuesday April 9, 2024, 9:00 AM - 12:30 PMLocation: Poster Section 21Poster Board Number: 4Published Abstract Number: 4503 Title: PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Antitumor Activity in Combination with BTK and BCL2 Inhibition in Various Lymphoid MalignanciesPresenter: Norman FultangSession Category: Experimental and Molecular TherapeuticsSession Title: Novel Biologic Therapies and Therapeutic TargetsSession Date and Time: Tuesday April 9, 2024, 1:30 PM - 5:00 PMLocation: Poster Section 27Poster Board Number: 14Published Abstract Number: 5966 Title: The Brain Penetrant CDK4/6 Inhibitor, PRT3645, is Highly Effective in Combination ...